LKT Labs

Biochemicals for Life Science Research

Vatalanib Dihydrochloride

Vatalanib Dihydrochloride

Product ID V0376
Cas No. 212141-51-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $59.00 In stock
5 mg $97.00 In stock
10 mg $127.00 In stock
25 mg $195.00 In stock
Bulk Quote

Quicklinks

Description

Vatalanib is an inhibitor of VEGFR that is currently in clinical trials for the treatment of myelodysplastic syndrome, lymphomas, non-small cell lung cancers (NSCLCs), and other cancers. Vatalanib exhibits anti-angiogenic, anti-metastatic, anticancer chemotherapeutic, and analgesic activities. In animal models with mammary carcinoma allografts, vatalanib decreases tumor vascularization. In animal models of pancreatic carcinoma, vatalanib inhibits tumor growth and metastasis and decreases microvessel density. Additionally, vatalanib decreases chronic neuropathic pain in animal models of chronic constriction injury, as inhibition of VEGFR2 inhibits signaling through neuropathic pain-mediating P2X (2/3) receptors.

Product Info

Cas No.

212141-51-0
Purity

≥98%
Formula

C20H15ClN4 • 2HCl
Formula Wt.

419.73
IUPAC Name

N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;dihydrochloride
Synonym

PTK-787 Dihydrochloride, PTK 787 Dihydrochloride, PTK787 Dihydrochloride, ZK-222584 Dihydrochloride, ZK 222584 Dihydrochloride, ZK222584 Dihydrochloride, CGP-797870 Dihydrochloride, ZK232934 Dihydrochloride
Melting Point

268-270°C
Appearance

Off-white to pinkish powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

V0376 MSDS PDF
Info Sheet

V0376 Info Sheet PDF

References

Gupta P, Mulkey F, Hasserjian RP, et al. A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs. 2013 Oct;31(5):1311-20. PMID: 23700288.

Liu S, Xu C, Li G, et al. Vatalanib decrease the positive interaction of VEGF receptor-2 and P2X2/3 receptor in chronic constriction injury rats. Neurochem Int. 2012 May;60(6):565-72. PMID: 22361062.

Gauler TC, Besse B, Mauguen A, et al. Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol. 2012 Mar;23(3):678-87. PMID: 21617019.

Hlushchuk R, Riesterer O, Baum O, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol. 2008 Oct;173(4):1173-85. PMID: 18787105.

Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm. 2001 Oct;16(5):359-70. PMID: 11776753.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B011460

    Baloxavir Marboxil

    Cap-dependent endonuclease inhibitor

    ≥ 99%
  • P2400

    Phenethyl Caffeate

    Found in propolis; 5-lipoxygenase inhibitor.

    ≥98%
  • M3344

    Milrinone

    PDE3 inhibitor.

    ≥98%
  • T0107

    Xylosyltaxol C

    Taxane found in species of Taxus; potential mic...

    ≥90%
  • E537335

    Enniatin B1

    Mycotoxin contaminant found in cereal grains.

    ≥98%
  • P5845

    Polydatin

    Stilbenoid glucoside found in Polygonum.

    ≥97%
  • A5033

    4-Aminosalicylic Acid

    Dihydrofolate reductase inhibitor.

    ≥98%
  • I0902

    Icaritin

    Flavonoid found in Epimedium.

    ≥98%
  • L5862

    Lopinavir

    HIV protease inhibitor, SERCA inhibitor.

    ≥98%
  • M324083

    Micafungin

    Echinocandin

    ≥95%
  • M4452

    MLN2480

    Raf inhibitor.

    ≥98%
  • T1298

    TDZD-8

    GSK-3β inhibitor.

    ≥98%
  • S8098

    SU-1498

    Tyrphostin; VEGFR inhibitor.

    ≥99%
  • E8419

    Everolimus

    mTORC1 inhibitor.

    ≥98%
  • B6959

    Bromosporine

    BRD2/4/9 and CECR2 inhibitor.

    ≥99%
  • S6019

    Speract

    Peptide, derived from egg outer envelope; K+ ch...

    ≥95%
  • C4274

    CKS-17

    Synthetic peptide, retroviral envelope protein ...

    ≥95%
  • L5993

    Loxoprofen Sodium Dihydrate

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • P327212

    Pifithrin-α-cyclic Hydrobromide

    p53 inhibitor

    ≥98%
  • T5946

    Toltrazuril

    Coccidiostat; mitochondrial respiration inhibit...

    ≥98%